Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Neoplasms 11Lung Neoplasms 11Small Cell Lung Carcinoma 8Thyroid Neoplasms 7Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma 6Breast Neoplasms 6Adenocarcinoma 6Colorectal Neoplasms 5Colonic Neoplasms 5Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Sarcoma 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Pancreatic Neoplasms 4Neuroendocrine Tumors 4Neoplasms by Site 4Melanoma 4Lung Diseases 4Endometrial Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Uterine Cervical Neoplasms 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Advanced Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡